In Segment A, individuals will get various doses and schedules of oral ABBV-744 tablet to establish Protected dosing routine. Supplemental contributors is going to be enrolled within the identified monotherapy dosign regimen. In Section B, members will get oral ruxolitinib and ABBV-744 will be presented as "increase-on" therapy. In Section https://klaust099gsc2.mycoolwiki.com/user